Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cybin Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CYBN
American
8731
https://www.cybin.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cybin Inc
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
- Mar 19th, 2024 3:53 pm
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
- Mar 18th, 2024 11:30 am
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
- Mar 15th, 2024 11:30 am
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
- Mar 14th, 2024 11:30 am
Announces Oversubscribed Private Placement of U.S. $150 Million
- Mar 13th, 2024 11:00 am
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
- Mar 13th, 2024 10:00 am
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
- Mar 13th, 2024 2:37 am
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
- Feb 27th, 2024 12:30 pm
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
- Feb 14th, 2024 12:45 pm
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
- Feb 7th, 2024 12:30 pm
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
- Jan 28th, 2024 10:02 pm
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
- Jan 23rd, 2024 12:30 pm
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
- Jan 8th, 2024 12:34 pm
Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs
- Jan 4th, 2024 12:32 pm
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
- Dec 6th, 2023 12:30 pm
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
- Dec 5th, 2023 12:30 pm
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
- Nov 30th, 2023 12:30 pm
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
- Nov 20th, 2023 12:30 pm
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023
- Nov 16th, 2023 12:30 pm
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
- Nov 15th, 2023 12:30 pm
Scroll